mitoxantrone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics; anthraquinone derivatives 1821 65271-80-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitoxantrone
  • mitoxantrone hydrochloride
  • dihydroxyanthraquinone
  • mitoxanthrone
  • mitozantrone
  • nimitoxantron
  • mitoxantrone dihydrochloride
  • mitoxantrone HCl
An anthracenedione-derived antineoplastic agent.
  • Molecular weight: 444.49
  • Formula: C22H28N4O6
  • CLOGP: 2.24
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 8
  • TPSA: 163.18
  • ALOGS: -2.78
  • ROTB: 12
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.59 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.78 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.25 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class AAK1,ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK6,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,DDR1,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,IRAK1,IRAK3,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK1,MARK2,MARK4,MELK,MET,MINK1,MKNK2,MST1R,MTOR,NTRK1,NTRK2,NUAK1,PAK2,PAK4,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKAA1,PRKAA2,PRKCD,PRKCZ,PRKD1,PRKDC,PTK2,SGK1,SIK2,SIK3,SRC,STK10,STK17A,STK33,STK4,SYK,TEK,TGFBR1,TNIK,TTK,TYRO3,UHMK1,ULK1,ULK2,YES1,ZAP70 150
kinase-selectivity-class AAK1,ACVR2B,ALK,AURKB,AXL,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK16,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,FLT4,GRK2,GSK3A,INSR,IRAK1,JAK2,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK12,MAPK7,MARK4,MELK,PIM3,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,TYRO3,ULK1,ULK2 48
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 8.337 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.030 % High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1987 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 450.88 28.07 234 7469 158115 90462629
Acute myeloid leukaemia 274.58 28.07 92 7611 20548 90600196
Myelodysplastic syndrome 215.36 28.07 77 7626 20826 90599918
Pancytopenia 171.86 28.07 114 7589 120149 90500595
Sepsis 168.77 28.07 132 7571 179682 90441062
Second primary malignancy 161.04 28.07 52 7651 10326 90610418
Neutropenia 133.37 28.07 127 7576 224777 90395967
Thrombocytopenia 129.75 28.07 121 7582 208604 90412140
Acute promyelocytic leukaemia 114.20 28.07 25 7678 1104 90619640
Haematotoxicity 109.83 28.07 41 7662 12494 90608250
Haemophagocytic lymphohistiocytosis 101.48 28.07 41 7662 15418 90605326
Leukaemia recurrent 91.96 28.07 22 7681 1445 90619299
Bronchopulmonary aspergillosis 84.47 28.07 33 7670 11365 90609379
Acute myeloid leukaemia recurrent 79.76 28.07 21 7682 2036 90618708
Bone marrow failure 78.26 28.07 43 7660 32178 90588566
Myelosuppression 72.09 28.07 49 7654 53542 90567202
Bacterial sepsis 69.46 28.07 23 7680 4932 90615812
Progressive multifocal leukoencephalopathy 67.99 28.07 31 7672 15624 90605120
Graft versus host disease 65.40 28.07 25 7678 8119 90612625
Venoocclusive liver disease 65.17 28.07 23 7680 5970 90614774
Congestive cardiomyopathy 64.21 28.07 24 7679 7330 90613414
Graft versus host disease in gastrointestinal tract 64.05 28.07 21 7682 4367 90616377
Disease progression 63.08 28.07 72 7631 156543 90464201
Febrile bone marrow aplasia 61.07 28.07 25 7678 9713 90611031
Chronic hepatitis 60.68 28.07 15 7688 1130 90619614
Aspergillus infection 58.52 28.07 25 7678 10798 90609946
Fungaemia 52.82 28.07 17 7686 3333 90617411
Strongyloidiasis 51.01 28.07 14 7689 1588 90619156
Lower respiratory tract infection fungal 50.65 28.07 10 7693 264 90620480
Mucormycosis 50.63 28.07 17 7686 3804 90616940
Paraspinal abscess 50.62 28.07 10 7693 265 90620479
Hypogammaglobulinaemia 49.08 28.07 22 7681 10652 90610092
Systemic inflammatory response syndrome 48.75 28.07 19 7684 6497 90614247
Cardiac failure 48.63 28.07 53 7650 109443 90511301
Metastases to bone marrow 47.83 28.07 11 7692 608 90620136
Acute lymphocytic leukaemia recurrent 47.83 28.07 15 7688 2706 90618038
Respiratory failure 46.91 28.07 54 7649 118364 90502380
Streptococcal bacteraemia 46.45 28.07 14 7689 2213 90618531
Drug resistance 46.15 28.07 30 7673 30419 90590325
Chloroma 45.11 28.07 9 7694 251 90620493
Septic shock 45.01 28.07 45 7658 84115 90536629
Stenotrophomonas infection 44.70 28.07 14 7689 2515 90618229
Bone marrow infiltration 44.47 28.07 11 7692 831 90619913
Cardiomyopathy 43.70 28.07 25 7678 20181 90600563
Arthralgia 43.68 28.07 7 7696 778515 89842229
Leukopenia 41.70 28.07 47 7656 100663 90520081
Multiple organ dysfunction syndrome 41.15 28.07 39 7664 68297 90552447
Escherichia infection 40.76 28.07 22 7681 15873 90604871
Pain 40.69 28.07 17 7686 996324 89624420
Klebsiella sepsis 40.64 28.07 12 7691 1769 90618975
Abdominal wall wound 39.73 28.07 7 7696 97 90620647
Product use in unapproved indication 38.65 28.07 87 7616 336149 90284595
Off label use 38.64 28.07 190 7513 1102062 89518682
Haemorrhagic adrenal infarction 38.43 28.07 6 7697 37 90620707
Myeloblast percentage decreased 37.89 28.07 6 7697 41 90620703
Refractory cytopenia with multilineage dysplasia 37.66 28.07 7 7696 133 90620611
Acute graft versus host disease 37.59 28.07 15 7688 5453 90615291
Hepatosplenic candidiasis 37.21 28.07 8 7695 324 90620420
Dysbiosis 36.80 28.07 11 7692 1691 90619053
Malignant neoplasm progression 36.18 28.07 45 7658 106825 90513919
Pyrexia 35.66 28.07 130 7573 660355 89960389
Hepatitis E 35.61 28.07 11 7692 1888 90618856
Abscess 34.62 28.07 21 7682 18870 90601874
Pneumonia klebsiella 34.20 28.07 12 7691 3060 90617684
Neoplasm progression 33.90 28.07 29 7674 44457 90576287
Aplastic anaemia 33.01 28.07 18 7685 13251 90607493
Chronic myeloid leukaemia 31.95 28.07 11 7692 2653 90618091
Mucosal inflammation 31.14 28.07 31 7672 57594 90563150
Granulicatella infection 30.70 28.07 6 7697 150 90620594
Stem cell transplant 30.19 28.07 10 7693 2144 90618600
Cardiotoxicity 29.86 28.07 16 7687 11373 90609371
Abdominal discomfort 29.85 28.07 3 7700 477325 90143419
Cerebral haemorrhage 29.40 28.07 24 7679 34498 90586246
Myelofibrosis 29.06 28.07 9 7694 1558 90619186
Pulmonary haemorrhage 29.02 28.07 14 7689 7999 90612745
Hepatic failure 28.46 28.07 25 7678 39703 90581041
Ejection fraction decreased 28.33 28.07 21 7682 26232 90594512

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 406.04 22.98 322 8483 185381 42427149
Myelodysplastic syndrome 192.78 22.98 94 8711 22651 42589879
Acute myeloid leukaemia 176.75 22.98 88 8717 22168 42590362
Septic shock 110.09 22.98 114 8691 91558 42520972
Neutropenia 107.42 22.98 166 8639 199265 42413265
Bone marrow failure 99.90 22.98 70 8735 33023 42579507
Mucormycosis 96.87 22.98 41 8764 7102 42605428
Second primary malignancy 94.57 22.98 44 8761 9531 42602999
Bronchopulmonary aspergillosis 85.34 22.98 52 8753 19377 42593153
Disease progression 77.80 22.98 120 8685 143536 42468994
Fungal infection 74.58 22.98 48 8757 19674 42592856
Myelosuppression 72.78 22.98 63 8742 40398 42572132
Venoocclusive liver disease 70.86 22.98 37 8768 10265 42602265
Acute lymphocytic leukaemia recurrent 63.05 22.98 25 8780 3666 42608864
Thrombocytopenia 62.87 22.98 128 8677 190151 42422379
Neutropenic colitis 61.74 22.98 26 8779 4444 42608086
Ameloblastoma 56.74 22.98 11 8794 102 42612428
Bacteraemia 55.45 22.98 44 8761 24996 42587534
Neoplasm progression 49.81 22.98 44 8761 28956 42583574
Aspiration bone marrow abnormal 48.86 22.98 10 8795 125 42612405
Multiple organ dysfunction syndrome 48.21 22.98 78 8727 96957 42515573
Minimal residual disease 47.18 22.98 13 8792 608 42611922
Cystitis haemorrhagic 46.65 22.98 25 8780 7304 42605226
Mucosal inflammation 46.31 22.98 54 8751 49320 42563210
Pancytopenia 45.89 22.98 85 8720 117658 42494872
Pneumonia fungal 44.09 22.98 26 8779 9120 42603410
Leukaemia recurrent 43.93 22.98 16 8789 1860 42610670
Lymphoma 42.50 22.98 30 8775 14291 42598239
Hypertensive hydrocephalus 42.32 22.98 8 8797 64 42612466
Drug resistance 41.75 22.98 43 8762 34205 42578325
Cardiotoxicity 40.78 22.98 23 8782 7422 42605108
Enamel anomaly 37.83 22.98 9 8796 232 42612298
Haematopoietic neoplasm 37.73 22.98 7 8798 50 42612480
Haematotoxicity 37.28 22.98 25 8780 10960 42601570
Tooth hypoplasia 37.15 22.98 9 8796 251 42612279
Neoplasm recurrence 34.82 22.98 15 8790 2709 42609821
Abscess fungal 34.65 22.98 9 8796 335 42612195
Klebsiella infection 34.23 22.98 24 8781 11308 42601222
Cytogenetic abnormality 33.71 22.98 11 8794 920 42611610
Aspergillus infection 33.29 22.98 27 8778 15810 42596720
Acute myeloid leukaemia refractory 31.61 22.98 7 8798 130 42612400
Acute myeloid leukaemia recurrent 31.17 22.98 15 8790 3497 42609033
Gallbladder adenocarcinoma 30.50 22.98 5 8800 15 42612515
Sepsis 30.10 22.98 100 8705 199234 42413296
Drug ineffective 29.93 22.98 227 8578 629970 41982560
Fungaemia 29.68 22.98 14 8791 3122 42609408
Refractory anaemia with an excess of blasts 29.68 22.98 8 8797 344 42612186
Disseminated mucormycosis 29.39 22.98 11 8794 1380 42611150
Clostridium bacteraemia 27.88 22.98 7 8798 227 42612303
Acute graft versus host disease in skin 27.88 22.98 18 8787 7406 42605124
Dystrophic calcification 27.29 22.98 5 8800 33 42612497
Febrile bone marrow aplasia 27.17 22.98 20 8785 10161 42602369
Progressive multifocal leukoencephalopathy 27.10 22.98 21 8784 11515 42601015
Large granular lymphocytosis 27.07 22.98 7 8798 256 42612274
Cytopenia 26.99 22.98 25 8780 17472 42595058
Respiratory tract infection fungal 26.94 22.98 9 8796 810 42611720
Differentiation syndrome 26.56 22.98 11 8794 1802 42610728
Fall 26.13 22.98 8 8797 234512 42378018
Chronic graft versus host disease 26.12 22.98 16 8789 6009 42606521
Genotoxicity 26.02 22.98 5 8800 44 42612486
Klebsiella sepsis 25.39 22.98 12 8793 2689 42609841
Pyrexia 25.24 22.98 153 8652 393889 42218641
Septal panniculitis 24.69 22.98 5 8800 59 42612471
Respiratory failure 24.65 22.98 70 8735 128062 42484468
Encephalopathy 24.38 22.98 36 8769 41297 42571233
Osteonecrosis 23.19 22.98 22 8783 15843 42596687

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 727.18 23.17 476 14218 316291 110258314
Acute myeloid leukaemia 433.32 23.17 170 14524 37940 110536665
Myelodysplastic syndrome 400.94 23.17 160 14534 37324 110537281
Second primary malignancy 249.77 23.17 93 14601 17975 110556630
Neutropenia 214.47 23.17 256 14438 374364 110200241
Bone marrow failure 182.80 23.17 107 14587 57741 110516864
Thrombocytopenia 173.14 23.17 222 14472 348663 110225942
Sepsis 158.78 23.17 206 14488 327140 110247465
Septic shock 157.11 23.17 145 14549 157383 110417222
Pancytopenia 149.94 23.17 161 14533 209452 110365153
Venoocclusive liver disease 145.59 23.17 60 14634 15147 110559458
Bronchopulmonary aspergillosis 132.17 23.17 69 14625 29794 110544811
Disease progression 129.99 23.17 161 14533 243873 110330732
Leukaemia recurrent 125.04 23.17 36 14658 3095 110571510
Myelosuppression 124.65 23.17 102 14592 94238 110480367
Haematotoxicity 123.71 23.17 59 14635 21023 110553582
Mucormycosis 119.22 23.17 47 14647 10581 110564024
Acute lymphocytic leukaemia recurrent 107.14 23.17 37 14657 5750 110568855
Acute promyelocytic leukaemia 99.49 23.17 27 14667 1869 110572736
Acute myeloid leukaemia recurrent 95.69 23.17 33 14661 5106 110569499
Drug resistance 91.83 23.17 69 14625 56305 110518300
Multiple organ dysfunction syndrome 87.04 23.17 104 14590 151606 110422999
Bacteraemia 82.98 23.17 58 14636 42332 110532273
Fungaemia 79.25 23.17 30 14664 6056 110568549
Progressive multifocal leukoencephalopathy 78.35 23.17 46 14648 24910 110549695
Haemophagocytic lymphohistiocytosis 78.19 23.17 50 14644 31509 110543096
Fungal infection 77.93 23.17 60 14634 50746 110523859
Neutropenic colitis 77.80 23.17 32 14662 8033 110566572
Aspergillus infection 77.24 23.17 46 14648 25570 110549035
Graft versus host disease 67.97 23.17 38 14656 18768 110555837
Neoplasm recurrence 65.28 23.17 25 14669 5207 110569398
Respiratory failure 64.29 23.17 108 14586 215224 110359381
Neoplasm progression 63.41 23.17 59 14635 64536 110510069
Klebsiella sepsis 63.36 23.17 23 14671 4130 110570475
Ameloblastoma 61.58 23.17 11 14683 102 110574503
Systemic inflammatory response syndrome 60.17 23.17 31 14663 13012 110561593
Drug ineffective 60.00 23.17 375 14319 1520165 109054440
Febrile bone marrow aplasia 59.63 23.17 34 14660 17431 110557174
Off label use 59.20 23.17 370 14324 1499815 109074790
Product use in unapproved indication 56.23 23.17 158 14536 447219 110127386
Clostridium bacteraemia 55.72 23.17 13 14681 485 110574120
Cardiotoxicity 55.33 23.17 32 14662 16849 110557756
Candida infection 55.31 23.17 48 14646 47961 110526644
Arthralgia 54.34 23.17 18 14676 779614 109794991
Pain 53.94 23.17 30 14664 954925 109619680
Refractory anaemia with an excess of blasts 53.65 23.17 14 14680 833 110573772
Lower respiratory tract infection fungal 53.49 23.17 14 14680 843 110573762
Cytogenetic abnormality 53.30 23.17 15 14679 1187 110573418
Pyrexia 53.30 23.17 248 14446 898017 109676588
Graft versus host disease in gastrointestinal tract 52.30 23.17 25 14669 8943 110565662
Mucosal inflammation 52.00 23.17 64 14630 96077 110478528
Chronic hepatitis 51.75 23.17 16 14678 1756 110572849
Pneumonia fungal 51.12 23.17 29 14665 14725 110559880
Differentiation syndrome 50.74 23.17 18 14676 3026 110571579
Cystitis haemorrhagic 50.57 23.17 27 14667 12182 110562423
Aplastic anaemia 49.30 23.17 34 14660 24274 110550331
Chloroma 48.85 23.17 13 14681 835 110573770
Bacterial sepsis 48.73 23.17 25 14669 10401 110564204
Cytopenia 47.12 23.17 36 14658 30080 110544525
Pruritus 46.98 23.17 10 14684 581550 109993055
Malignant neoplasm progression 46.14 23.17 83 14611 174484 110400121
Stenotrophomonas infection 45.72 23.17 20 14674 5838 110568767
Fatigue 45.55 23.17 57 14637 1215901 109358704
Enterococcal infection 44.90 23.17 30 14664 20336 110554269
Cardiomyopathy 43.71 23.17 36 14658 33489 110541116
Klebsiella infection 42.98 23.17 29 14665 19980 110554625
Hepatic failure 42.50 23.17 49 14645 68690 110505915
Paraspinal abscess 41.80 23.17 10 14684 416 110574189
Diffuse large B-cell lymphoma recurrent 41.17 23.17 19 14675 6280 110568325
Leukopenia 40.92 23.17 72 14622 148719 110425886
Nasopharyngitis 40.90 23.17 3 14691 394358 110180247
Staphylococcal infection 40.16 23.17 48 14646 69896 110504709
Acute myeloid leukaemia refractory 40.06 23.17 9 14685 283 110574322
Respiratory tract infection fungal 38.85 23.17 12 14682 1312 110573293
Drug hypersensitivity 38.35 23.17 7 14687 454083 110120522
Tooth hypoplasia 38.26 23.17 9 14685 348 110574257
Hypogammaglobulinaemia 38.18 23.17 27 14667 20049 110554556
White blood cell count decreased 38.05 23.17 90 14604 229300 110345305
Metastases to bone marrow 37.57 23.17 11 14683 1003 110573602
Stomatococcal infection 37.52 23.17 9 14685 379 110574226
Stem cell transplant 37.45 23.17 16 14678 4411 110570194
Hepatosplenic candidiasis 37.37 23.17 10 14684 656 110573949
Haematopoietic neoplasm 37.17 23.17 7 14687 89 110574516
Cardiac failure 37.15 23.17 79 14615 187547 110387058
Abdominal wall wound 37.02 23.17 7 14687 91 110574514
Fall 36.95 23.17 17 14677 603465 109971140
Escherichia infection 36.23 23.17 28 14666 23788 110550817
Enamel anomaly 36.10 23.17 8 14686 236 110574369
Lymphoma 35.78 23.17 26 14668 20145 110554460
Refractory cytopenia with multilineage dysplasia 35.51 23.17 8 14686 255 110574350
Disseminated intravascular coagulation 35.38 23.17 35 14659 41251 110533354
Myeloblast percentage decreased 35.21 23.17 6 14688 41 110574564
Bone marrow infiltration 34.74 23.17 10 14684 858 110573747
Pain in extremity 34.33 23.17 11 14683 487107 110087498
Hyperammonaemic encephalopathy 34.30 23.17 16 14678 5418 110569187
Hypertensive hydrocephalus 34.14 23.17 5 14689 10 110574595
Chronic graft versus host disease 33.87 23.17 19 14675 9438 110565167
Graft versus host disease in skin 33.47 23.17 18 14676 8236 110566369
Acute graft versus host disease 33.37 23.17 21 14673 12860 110561745
Chronic lymphocytic leukaemia recurrent 32.87 23.17 10 14684 1039 110573566
Pseudomonas infection 32.38 23.17 28 14666 27825 110546780
Acute graft versus host disease in skin 31.63 23.17 19 14675 10721 110563884
Chronic myeloid leukaemia 31.45 23.17 14 14680 4259 110570346
Colitis 31.40 23.17 52 14642 102271 110472334
Pneumonia klebsiella 31.27 23.17 16 14678 6616 110567989
Abscess fungal 31.13 23.17 8 14686 448 110574157
Pulmonary haemorrhage 30.99 23.17 22 14672 16434 110558171
Acute lymphocytic leukaemia 30.39 23.17 15 14679 5750 110568855
Neutrophil count decreased 30.04 23.17 56 14638 120885 110453720
Escherichia bacteraemia 29.98 23.17 18 14676 10146 110564459
Nausea 29.91 23.17 76 14618 1235614 109338991
Disseminated mucormycosis 29.69 23.17 11 14683 2091 110572514
Osteonecrosis 29.65 23.17 29 14665 33712 110540893
Dysbiosis 29.54 23.17 11 14683 2121 110572484
Insomnia 29.51 23.17 6 14688 360584 110214021
Strongyloidiasis 29.38 23.17 14 14680 4972 110569633
Dizziness 29.04 23.17 30 14664 698163 109876442
Fungal sepsis 29.02 23.17 11 14683 2226 110572379
Venoocclusive disease 29.02 23.17 15 14679 6335 110568270
Encephalopathy 28.74 23.17 44 14650 81011 110493594
Weight increased 28.65 23.17 10 14684 419634 110154971
Hepatitis B 28.29 23.17 17 14677 9595 110565010
Tumour lysis syndrome 28.05 23.17 27 14667 30774 110543831
Alopecia 27.98 23.17 7 14687 364746 110209859
Cytokine release syndrome 27.55 23.17 40 14654 70266 110504339
Platelet count decreased 27.54 23.17 80 14614 230363 110344242
Granulicatella infection 27.45 23.17 6 14688 166 110574439
Cytomegalovirus infection 27.44 23.17 35 14659 54409 110520196
Portal hypertension 27.31 23.17 16 14678 8621 110565984
Streptococcal bacteraemia 27.18 23.17 13 14681 4656 110569949
Chromosomal deletion 27.14 23.17 6 14688 175 110574430
Aspiration bone marrow abnormal 27.04 23.17 6 14688 178 110574427
Blood culture positive 26.74 23.17 16 14678 8960 110565645
Pseudomonal sepsis 26.63 23.17 16 14678 9030 110565575
Acute febrile neutrophilic dermatosis 26.49 23.17 13 14681 4923 110569682
Hyperbilirubinaemia 26.27 23.17 26 14668 30645 110543960
Lymphopenia 25.44 23.17 29 14665 40141 110534464
Large granular lymphocytosis 25.35 23.17 7 14687 517 110574088
Ejection fraction decreased 25.03 23.17 29 14665 40851 110533754
Acute graft versus host disease in intestine 24.85 23.17 13 14681 5626 110568979
Hepatitis E 24.70 23.17 12 14682 4447 110570158
Hypertension 24.69 23.17 19 14675 510065 110064540
Chromosome analysis abnormal 24.43 23.17 6 14688 279 110574326
Hepatic function abnormal 24.27 23.17 43 14651 89252 110485353
Dyspnoea 23.84 23.17 72 14622 1106800 109467805
Fusarium infection 23.39 23.17 10 14684 2761 110571844
Aplasia 23.37 23.17 14 14680 7859 110566746
Streptococcal sepsis 23.23 23.17 12 14682 5060 110569545

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
FDA MoA N0000000176 Topoisomerase Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018689 Sensory System Agents
MeSH PA D059005 Topoisomerase II Inhibitors
FDA EPC N0000175609 Topoisomerase Inhibitor
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent

Related Drugs by ATC class:

L01DB Anthracyclines and related substances 10 drugs
aclarubicinamrubicindaunorubicindoxorubicinepirubicinidarubicinpirarubicinpixantronevalrubicinzorubicin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378
Metastatic Prostate Carcinoma indication
Follicular non-Hodgkin's lymphoma off-label use 308121000
Metastatic Breast Carcinoma off-label use
Progressive Diffuse Large B-Cell Lymphoma off-label use
Mycosis contraindication 3218000 DOID:1564
Viral disease contraindication 34014006 DOID:934
Chronic heart failure contraindication 48447003
Hepatic failure contraindication 59927004
Acute infectious disease contraindication 63171007
Leukopenia contraindication 84828003 DOID:615
Left heart failure contraindication 85232009
Bacterial infectious disease contraindication 87628006
Radiation oncology AND/OR radiotherapy contraindication 108290001
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.37 acidic
pKa2 10.7 acidic
pKa3 9.13 Basic
pKa4 8.52 Basic
pKa5 4.01 Basic
pKa6 1.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR IC90 5.96 WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.84 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.31 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.73 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.74 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.11 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.05 DRUG MATRIX
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter IC50 6.29 WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter Kact 5.16 WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.27 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.90 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.69 DRUG MATRIX
Serine/threonine-protein kinase pim-1 Kinase IC50 7.29 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.36 CHEMBL
DNA-(apurinic or apyrimidinic site) lyase Enzyme IC50 5.70 CHEMBL
Tyrosine-protein kinase BTK Kinase IC50 6 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase IC50 5.52 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.13 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 6.72 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.28 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.22 CHEMBL
DNA-3-methyladenine glycosylase Enzyme IC50 5.60 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.53 DRUG MATRIX
TAR DNA-binding protein 43 Cytosolic other IC50 5 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.75 DRUG MATRIX
Integrase Enzyme IC50 5.42 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase AC50 5.02 CHEMBL

External reference:

IDSource
4019842 VUID
N0000147929 NUI
D02166 KEGG_DRUG
70476-82-3 SECONDARY_CAS_RN
4019527 VANDF
4019842 VANDF
C0026259 UMLSCUI
CHEBI:50729 CHEBI
MIX PDB_CHEM_ID
CHEMBL58 ChEMBL_ID
CHEMBL1417019 ChEMBL_ID
D008942 MESH_DESCRIPTOR_UI
DB01204 DRUGBANK_ID
7242 IUPHAR_LIGAND_ID
4922 INN_ID
BZ114NVM5P UNII
4212 PUBCHEM_CID
203129 RXNORM
5124 MMSL
81184 MMSL
d00306 MMSL
002676 NDDF
004828 NDDF
108791001 SNOMEDCT_US
386913001 SNOMEDCT_US
412249002 SNOMEDCT_US
BZ114NVM5P INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 63323-132 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 15 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 71288-178 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 25 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 71288-179 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 25 sections